Putting roadblocks on scientific & medical research on Cannabis #unacceptable
Make a Difference
Why Research Matters
Thousands of studies conducted in universities and research labs across the globe have also demonstrated that certain cannabinoids (THC, CBD, etc.) inhibit tumor growth by promoting cell death (apoptosis), reducing cell growth, stopping metastasis and blocking the development of blood vessels (angiogenesis) that supply the tumor. Some of these research found that the cannabinoids, when used in combination, become even more potent killers of cancerous cells.
Understanding ECS and the effect of cannabis molecules on ECS can radicalize the current medical system of managing and treating complicated diseases.
However, key gaps remain between what has been researched in a petri dish and in animals in a laboratory settings versus what will be observed in clinical trials in humans for conclusive evidence on the therapeutic benefits of cannabis, understanding of the specific mechanisms involved, and how the outcomes may vary based on generic differences, type of disease, stage of the disease, dosage, toxicity, side effects and many other external factors. Only research and human clinical trial can help better understand the mechanisms by which cannabinoids could be utilized as adjunctive treatment of various diseases.
Since cannabis is currently classified as a Schedule 1 drug, The Cannabis Foundation is partnering with doctors, research institutes and universities that are currently working with various government bodies like FDA (Food and Drug Administration), DEA (Drug Enforcement Agency), NIDA (National Institute of Drug Abuse), NIH (National Institute of Health), HHS (Human and Health Services) and are able to overcome various federal and state regulatory hurdles to push scientific cannabis research and human clinical trials for cannabis in various medical treatments.